More than 1.4 million patients are on renal replacement therapy worldwide. Mortality in patients with end-stage renal disease (ESRD) is as high as that seen in some types of metastatic cancer, and premature cardiovascular disease is the major killer in ESRD. Several publications in 2011 addressed how interventions can modify cardiovascular risk factors and improve outcomes.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Impact of a modified data capture period on Liu comorbidity index scores in Medicare enrollees initiating chronic dialysis
BMC Nephrology Open Access 27 February 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Carrero, J. J. & Stenvinkel, P. Of persistent inflammation as a catalyst for other risk factors in chronic kidney disease. a hypothesis proposal. Clin. J. Am. Soc. Nephrol. 4, S49–S55 (2009).
Tripepi, G. et al. Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Clin. J. Am. Soc. Nephrol. 7, 1714–1721 (2011).
Hung, A. M., Ellis, C. D., Shintani, A., Booker, C. & Ikizler, T. A. IL-1β receptor antagonist reduces inflammation in hemodialysis patients. J. Am. Soc. Nephrol. 22, 437–442 (2011).
Baigent, C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377, 2181–2192 (2011).
Holdaas, H. et al. Rosuvastatin in diabetic hemodialysis patients. J. Am. Soc. Nephrol. 22, 1335–1341 (2011).
Winkelmayer, W. C., Patrick, A. R., Liu, J., Brookhart, M. A. & Setoguchi, S. The increasing prevalence of atrial fibrillation among hemodialysis patients. J. Am. Soc. Nephrol. 22, 349–357 (2011).
Winkelmayer, W. C., Liu, J., Setoguchi, S. & Choudhry, N. K. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin. J. Am. Soc. Nephrol. http://dx.doi.org/10.2215/CJN.04550511.
Granger, C. B. et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365, 981–992 (2011).
Eknoyan, G. et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N. Engl. J. Med. 347, 2010–2019 (2002).
Chertow, G. M. et al. In-center hemodialysis six times per week versus three times per week. N. Engl. J. Med. 363, 2287–2300 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P. Stenvinkel declares an association with the following company: Gambro (scientific advisor). P. Bárány declares no competing interests.
Rights and permissions
About this article
Cite this article
Stenvinkel, P., Bárány, P. Can cardiovascular risk in dialysis patients be decreased?. Nat Rev Nephrol 8, 72–74 (2012). https://doi.org/10.1038/nrneph.2011.212
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2011.212